Eiger BioPharmaceuticals
Quick facts
Phase 3 pipeline
- Placebo Lonafarnib · Oncology
Lonafarnib inhibits farnesyltransferase, blocking the post-translational modification of proteins involved in cell proliferation and survival.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: